SUPPORTING INFECTIOUS DISEASE RESEARCH

# Macacine Herpesvirus 1, E2490, Gamma-Irradiated

## Catalog No. NR-44259

This reagent is the tangible property of the U.S. Government.

## For research use only. Not for human use.

## **Contributor and Manufacturer:**

World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, USA, under government contract

## **Product Description:**

Gamma-irradiated macacine herpesvirus 1,  $E2490^{1.2}$  was prepared from infected Vero E6 cell pellets. Cell pellets were resuspended in 50 mM sodium borate and 120 mM sodium chloride (pH 9) containing 1% Triton X-100, gammairradiated (5 × 10<sup>6</sup> RADs) on dry ice, and sonicated. Cell debris was removed by centrifugation and the supernatant containing the irradiated antigen was aliquoted and vialed.

NR-44259 was tested for residual virus following the procedure described by Towner et al.<sup>3</sup> No residual virus was recovered.

## Material Provided:

Each vial contains 100  $\mu$ L of irradiated antigen in 50 mM sodium borate and 120 mM sodium chloride (pH 9) containing 1% Triton X-100. The vial should be centrifuged prior to opening.

## Packaging/Storage:

NR-44259 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

## Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Macacine Herpesvirus 1, E2490, Gamma-Irradiated, NR-44259."

## Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see <u>www.cdc.gov/biosafety/publications/bmbl5/index.htm</u>.

## Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal.  $ATCC^{\circledast}$  and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government,  $ATCC^{\circledast}$ , their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

## **Use Restrictions:**

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

## **References:**

- Hull, R. N., and J. C. Nash. "Immunization against B Virus Infection. I. Preparation of an Experimental Vaccine." <u>Am. J. Hyg.</u> 71 (1960): 15-28. PubMed: 14403944.
- Hull, R. N., et al. "Immunization against B Virus Infection. II. Further Laboratory and Clinical Studies with an Experimental Vaccine." <u>Am. J. Hyg.</u> 76 (1962): 239-251. PubMed: 13955640.
- Towner, J. S., et al. "High-Throughput Molecular Detection of Hemorrhagic Fever Virus Threats with Applications for Outbreak Settings." <u>J. Infect. Dis</u>. 196 Suppl. 2 (2007) S205-S212. PubMed: 17940951.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.



BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898